Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option
February 20, 2026 15:10 ET | Source: Eupraxia Pharmaceuticals Inc. VICTORIA, British…
Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
Announced first patient dosed in the Phase 2b placebo-controlled portion of the…
